COVID-19 ile İlişkili Diabetes Mellitus

WHO. WHO coronavirus disease (COVID-19) dashboard. 2022. (14 mart 2022 tarihinde https://covid19.who.int/) adresinden ulaşılmıştır

Jivanji CJ, Asrani VM, Windsor JA, et al. New-onset diabetes after acute and critical illness: A Systematic Review. Mayo Clinic Proceedings; 2017;92(5):762-773. doi: 10.1016/j.mayocp.2016.12.020

Parise R, Deruiter J, Ren J, et al. Impact of COVID-19 therapy on hyperglycemia. Diabetes & Vascular Disease Research; 2022;19(3):14791641221095091. doi: 10.1177/14791641221095091

Le VT, Ha QH, Tran MT, et al. Hyperglycemia in severe and critical COVID-19 patients: risk factors and outcomes. Cureus; 2022;14(8):e27611. doi: 10.7759/cureus.27611

Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. Journal of Diabetes Science and Technology; 2020;14(4):813-821. doi:10.1177/1932296820924469

Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes, Obesity & Metabolism; 2020;22(10):1897-1906. doi: 10.1111/dom.14099

Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Research and Clinical Practice; 2020;164:108166. doi: 10.1016/j.diabres.2020.108166

Ren H, Yang Y, Wang F, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovascular Diabetology; 2020;19(1):58. doi: 10.1186/s12933-020-01035-2.

Farag AA, Hassanin HM, Soliman HH, et al. Newly diagnosed diabetes in patients with COVID-19: different types and short-term outcomes. Tropical Medicine and Infectious Disease; 2021;6(3):142. doi: 10.3390/tropicalmed6030142.

Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutrition & Diabetes; 2021;11(1):21. doi: 10.1038/s41387-021-00163-2

Metwally AA, Mehta P, Johnson BS, Nagarjuna A, Snyder MP. COVID-19-induced new-onset diabetes: trends and technologies. Diabetes; 2021;70(12):2733-2744. doi: 10.2337/dbi21-0029

Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews (Endocrinology); 2021; 17:11-30

Muller JA, Gross R, Conzelmann C, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nature Metabolism; 2021;3(2):149-165. doi:10.1038/s42255-021-00347-1

Yang JK, Lin SS, Ji XJ, et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetologica; 2010;47(3):193-199. doi: 10.1007/s00592-009-0109-4

Boddu SK, Aurangabadkar G, Kuchay MS. New onset diabetes, type 1 diabetes and COVID-19. Diabetes & Metabolic Syndrome; 2020;14(6):2211-2217. doi: 10.1016/j.dsx.2020.11.012

Wu CT, Lidsky PV, Xiao Y, Matthias S, et al.. SARS-CoV-2 infects human pancreatic b cells and elicits b cell impairment. Cell Metabolism;2021;33(8):1565–1576.doi: 10.1016/j.cmet.2021.05.013

Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metabolism Research Reviews. 2020;36(7):e3319. doi: 10.1002/dmrr.3319

Diabetes now affects one in 10 adults worldwide. (14 Mart 2022 tarihinde

https://www.idf.org/news/240:diabetes-now-affects-one-in-10-adults-worldwide.html) adresinden ulaşılmıştır.

Deschasaux-Tanguy M, Druesne-Pecollo N, Esseddik Y, et al. Diet and physical activity during the coronavirus disease 2019 (COVID-19) lockdown (March-May 2020): results from the French NutriNet-Sante cohort study. The American Journal of Clinical Nutrition; 2021;113(4):924-938. doi: 10.1093/ajcn/nqaa336.

Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic medicine : A Journal of the British Diabetic Association; 2006;23(6):623-628. doi:10.1111/j.1464-5491.2006.01861.x

Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet; 2000;355(9206):773-778. doi: 10.1016/S0140-6736(99)08415-9.

Gerganova A, Assyov Y, Kamenov Z. Stress hyperglycemia, diabetes mellitus and COVID-19 infection: risk factors, clinical outcomes and post-discharge implications. Frontiers in clinical diabetes and healthcare;2022; 3:1-13. doi: 10.3389/fcdhc.2022.826006

Barbu MG, Thompson RJ, Thompson DC, et al. The impact of SARS-CoV-2 on the most common comorbidities-A retrospective study on 814 COVID-19 deaths in romania. Frontiers in Medicine; 2020;7:567199. doi: 10.3389/fmed.2020.567199

Erener S. Diabetes, infection risk and COVID-19. Molecular metabolism; 2020;39:101044. doi: 10.1016/j.molmet.2020.101044

Selvin E, Juraschek SP. Diabetes epidemiology in the COVID-19 pandemic. Diabetes Care; 2020;43(8):1690-1694. doi: 10.2337/dc20-1295

Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. The Journal of the American Medical Association; 2020;323(13):1239-1242. doi: 10.1001/jama.2020.2648

Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The lancet. Diabetes & Endocrinology; 2020;8(10):813-822. doi: 10.1016/S2213-8587(20)30272-2

Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. British Medical Journal; 2020;369:m1966. doi: 10.1136/bmj.m1966

Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes care; 2020;43(7):1392-1398. doi: 10.2337/dc20-0576

Sobngwi E, Choukem SP, Agbalika F, et al. Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-saharan africans. The Journal of the American Medical Association; 2008;299(23):2770-2776. doi: 10.1001/jama.299.23.2770

Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia; 2020;63(10):2102-2111. doi: 10.1007/s00125-020-05209-1

Chee JY, Tan SK, Yeoh E. Dissecting the interaction between COVID-19 and diabetes mellitus. Journal of Diabetes Investigation; 2020; 11: 1104–1114. doi: 10.1111/jdi.13326

Amin S, Lux A, O'Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. British Journal of Clinical Pharmacology; 2019;85(1):37-46. doi: 10.1111/bcp.13780

Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. The lancet. Diabetes & Endocrinology; 2020;8(6):546-550. doi: 10.1016/S2213-8587(20)30152-2

Cai L, Cai Y, Lu ZJ, et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of Clinical Pharmacy and Therapeutic; 2012; 37: 386–398.

Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. The Journal of the American Medical Association; 2007;298(2):194-206. doi: 10.1001/jama.298.2.194

Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews; 2008;2008(2):CD006739. doi: 10.1002/14651858.CD006739.pub2

Cai L, Cai Y, Lu ZJ, et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of Clinical Pharmacy and Therapeutics; 2012;37(4):386-398. doi: 10.1111/j.1365-2710.2011.01323.x.

Wvan der Zanden R, de Vries F, Lalmohamed A, et al. Use of Dipeptidyl-Peptidase-4 inhibitors and the risk of pneumonia: A Population-based Cohort study. PloS One. 2015;10(10):e0139367. doi: 10.1371/journal.pone.0139367

Song W, Wang Y, Wang N, et al. Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry. Virology; 2014;471-473:49-53. doi: 10.1016/j.virol.2014.10.006

Drucker DJ. Coronavirus infections and Type 2 diabetes-shared pathways with therapeutic implications. Endocrine Reviews; 2020;41(3): bnaa011. doi: 10.1210/endrev/bnaa011

Krejner Bienias A, Grzela K, Grzela T. DPP4 inhibitors and COVID 19–holy grail or another dead end? Archivum Immunologiae et Therapiae Experimentalis; 2021; 69:1. doi:10.1007/s00005-020-00602-5

Lee YS, Jun HS. Anti-Inflammatory Effects of GLP-1-based therapies beyond glucose control. Mediators of Inflammation. 2016;2016:3094642. doi: 10.1155/2016/3094642

Bloodworth MH, Rusznak M, Pfister CC, et al. Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. The Journal of Allergy and Clinical Immunology; 2018;142(2):683-687 e612. doi: 10.1016/j.jaci.2018.01.053

Banerjeea Y, Stoianc AP, Silva-Nunesd J, et al. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opinion on Drug Safety; 2021: 1–7. doi:10.1080/14740338.2021.1970744

Zhang W, Xu YZ, Liu B, et al. Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. The Scientific World Journal. 2014;2014:603409. doi: 10.1155/2014/603409

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. Respiratory Medicine; 2020;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8

Carboni E, Carta AR, Carboni E. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Medical Hypotheses; 2020;140:109776. doi: 10.1016/j.mehy.2020.109776

Gorricho J, Garjon J, Alonso A, et al. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study. British Journal of Clinical Pharmacology; 2017;83(9):2034-2044. doi: 10.1111/bcp.13288

Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews. Endocrinology; 2021;17(1):11-30. doi:10.1038/s41574-020-00435-4

Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. The Journal of Clinical Endocrinology and Metabolism; 2003;88(3):1082-1088. doi: 10.1210/jc.2002-021478

Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology. Endocrinology and Metabolism; 2020;318(5):E736-E741. doi: 10.1152/ajpendo.00124.2020

Sanders JM, Monogue ML, Jodlowski TZ et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A Review. The Journal of the American Medical Association; 2020;323(18):1824-1836. doi: 10.1001/jama.2020.6019

Prokunina-Olsson L, Alphonse N, Dickenson RE, et al. COVID-19 and emerging viral infections: The case for interferon lambda. The Journal of Experimental Medicine; 2020;217(5): e20200653. doi: 10.1084/jem.20200653

Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinology; 2020; 8: 546–50. doi:10.1016/S2213-8587(20)30152-2

Anderson EJ, Daugherty MA, Pickering LK, et al. Protecting the community through child vaccination. Clinical Infectious Diseases; 2018;67(3):464-471. doi:10.1093/cid/ciy142

Goeijenbier M, van Sloten TT, Slobbe L, et al. Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine; 2017;35(38):5095-5101. doi: 10.1016/j.vaccine.2017.07.095

McElhaney JE, Garneau H, Camous X, et al. Predictors of the antibody response to influenza vaccination in older adults with type 2 diabetes. British Medical Journal Open Diabetes Research & Care; 2015;3(1):e000140. doi: 10.1136/bmjdrc-2015-000140

Seo YB, Baek JH, Lee J, et al. Long-term immunogenicity and safety of a conventional influenza vaccine in patients with Type 2 diabetes. Clinical and Vaccine Immunology; 2015;22(11):1160-1165. doi: 10.1128/CVI.00288-15

Wang IK, Lin CL, Chang YC, et al. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine; 2013;31(4):718-724. doi: 10.1016/j.vaccine.2012.11.017

İlin S, Kuşkonmaz SM. Diabetes And Coronavirus Disease 2019 (COVID-19). Ankara Eğt. Arş. Hast. Derg., 2021; 54(3): 471-478. doi: 10.20492/aeahtd.922692